38 results on '"Han, Jindi"'
Search Results
2. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
3. Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism
4. The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies
5. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
6. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails
7. Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score- matched cohort study
8. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
9. sj-docx-1-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
10. sj-docx-2-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
11. sj-docx-4-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
12. sj-pdf-3-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
13. Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
14. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
15. Spatial and temporal distributions of nitrogen, phosphorus and heavy metals in the intertidal sediment of the Chang jiang River Estuary in China
16. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
17. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
18. Denitrification performance of Pseudomonas fluorescens Z03 immobilized by graphene oxide-modified polyvinyl-alcohol and sodium alginate gel beads at low temperature
19. Salvage treatment with anlotinib for advanced non‐small cell lung cancer
20. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
21. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC
22. Icotinib as first-line or maintenance therapy in patients with advanced lung adenocarcinoma with positive EGFR mutation and the influence of cytokines shift on survival.
23. Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.
24. Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.
25. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
26. Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer
27. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
28. Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.
29. Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients
30. Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.
31. Circulating PD ‐ L 1 in NSCLC patients and the correlation between the level of PD ‐ L 1 expression and the clinical characteristics
32. Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer
33. Circulating PD- L1 in NSCLC patients and the correlation between the level of PD- L1 expression and the clinical characteristics.
34. The overall survival benefit in Chinese ALK + NSCLC patients received targeted therapies.
35. [Timing of Brain Radiation Therapy Impacts Outcomes in Patients with Non-small Cell Lung Cancer Who Develop Brain Metastases].
36. [Effects of Local Radiation Combined with Chemotherapy in the treatment of Patients with Extensive-stage Small Cell Lung Cancer].
37. [Multivariate analysis of prognostic factors in the eldly patients with small cell lung cancer: a study of 160 patients].
38. [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.